On the stock market since 2018, it operates in the world of health and science. It has 350 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 31% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
There is growth, but not at top-of-the-class tempo.
The stock has been running stronger than the market lately.
No real weak spot in any of the five subjects — a balanced report card.
The stock trades 52% below its peak. The market has trimmed its expectations for the company.
Over the last 3 years, sales grew about 26% a year on average.
Sales run at $297.2M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 20 buys and 14 sells. Management buying with its own money is usually read as a good sign.
A loss of $51.6M against $297.2M in annual sales.
At the current pace of spending, the cash lasts about 1 year. After that, the company needs to find new money.
On our five-subject report card, EOLS sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: EOLS is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (55/100) says the stock isn’t cheap.